Mayo Clinic announced that it launched a new SARS-CoV-2 neutralizing antibody test in support of efforts to establish therapies and vaccines for COVID-19.
As part of the Expanded Access Program for Convalescent Plasma and other critical research efforts, Mayo Clinic intends to make the test available to select labs, blood banks and biopharma clients later this month.
Mayo Clinic designed the new test to measure the level of neutralizing antibodies against SARS-CoV-2, the virus causing COVID-19. The test provides semi-quantitative detection of total neutralizing antibodies in human serum. After infection, most will develop an immune response to COVID-19, including the production of neutralizing antibodies against the SARS-CoV-2 spike glycoprotein. However, it’s currently unknown for how long the neutralizing antibodies persist after infection.
The test should only be ordered upon confirmation of prior infection and it should not be used to diagnose …